David Hung Net Worth

Track Major Insider Updates On X/Twitter

Last Updated: 1 month, 2 weeks ago

David Hung has an estimated net worth of at least $324.0 million*, as of Oct. 29, 2025. They own 59.3 million shares of NUVB stock. They have sold 999 shares of NUVB stock since 2021, for an estimated $-1.7 million.

David Hung $NUVB SEC Form 4 Insider Trading

David Hung has filed a total of 3 insider trades in $NUVB since 2021. Their most recent trade was a purchase of 500,000 shares, made on Jun 16, 2025. Their largest trade was a purchase of 500,000 shares, made on Jun 16, 2025. We estimate that they now own 59.3 million shares of $NUVB, worth an estimated $325.7 million.

Insider Trading at $NUVB

There have been a total of 46 insider trades reported at $NUVB since 2021, with 7.8 million shares purchased and 7.9 million shares sold. The most active insider traders in $NUVB stock have been Dongfang Liu, David Hung, and Gary Hattersley. The most recent trade was a sale of 150,000 shares reported by Dongfang Liu (CHIEF MEDICAL OFFICER), made on Dec 01, 2025.

History of Insider Stock Trades by David Hung

Company Ticker	Purchase / Sale	Shares	Date	Disclosed (EST)
NUVB	Purchase	500,000	Jun 16, 2025	June 18, 2025, 4:05 p.m.
NVCR	Sale	999	Jun 03, 2025	June 4, 2025, 4:11 p.m.
NUVB	Purchase	200,000	Apr 04, 2025	April 8, 2025, 9:30 p.m.
NUVB	Purchase	300,000	Apr 07, 2025	April 8, 2025, 9:30 p.m.

$NUVB Executives and Stock Owners with Insider Trades

Dongfang Liu, CHIEF MEDICAL OFFICER
David Hung, PRESIDENT AND CEO
Gary Hattersley, CHIEF SCIENTIFIC OFFICER
Kerry Wentworth, CHIEF REGULATORY OFFICER
Philippe Sauvage, Chief Financial Officer
Colleen Sjogren, Chief Commercial Officer
David C. Hanley, CHIEF TECHNICAL OPERATIONS
Junyuan Jerry Wang, CEO, ANHEART THERAPEUTICS LTD.
Stacy Markel, CHIEF PEOPLE OFFICER

*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.